Clinical trial
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168 · Daiichi Sankyo, Industry · Recruiting
Key facts
| NCT number | NCT05875168 |
|---|---|
| Title | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors |
| Official title | Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumor, Metastatic Solid Tumor |
| Intervention type | Drug |
| Interventions | DS-3939a |
| Enrollment | 540 |
| Start date | Aug 18, 2023 |
| Primary completion | Mar 17, 2026 |
| Completion | Feb 15, 2027 |
| First posted | May 25, 2023 |
| Last update posted | Jan 12, 2026 |
| Countries | Belgium, Canada, China, France, Japan, South Korea, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: